Jiangsu Kanion Pharmaceutical Co. Ltd.SSE: 600557

2025 Semi-annual Report

Aug 28, 2025 · Issued by Jiangsu Kanion Pharmaceutical Co. Ltd. via Shanghai Stock Exchange

Filed with SSE · Aug 28, 2025

On 6ix: 6ix.com/news/2025-semi-annual-report-59

2025 Semi-annual Report

The abstract is for reference only. Please refer to the full text of the announcement on the very day.

Link of Full Text for Reference:
View Attachment

6ix hasn’t read this filing yet.

Jiangsu Kanion Pharmaceutical Co. Ltd. on 6ix

Earlier from Jiangsu Kanion Pharmaceutical

Announcement on the Receipt of the Clinical Trial Approval Notice for Jinzhen Oral Liquid with Increased IndicationsAug 23, 2025
Announcement on the Receipt of the Clinical Trial Approval Notice for Jianpi Shugan Guben GranulesAug 19, 2025
Announcement on Obtaining Drug Registration Certificate for Shenpu GranulesAug 4, 2025
Announcement on the Receipt of the Clinical Trial Approval Notice for KYS2301 GelJul 4, 2025
Announcement on Outgoing of ChairmanJun 21, 2025

Later from Jiangsu Kanion Pharmaceutical

Announcement on Pledge of Some Shares Held by Shareholders with Over 5% SharesSep 27, 2025
Announcement on Wholly-owned Subsidiary's Drug Additional Indication Obtaining Clinical Trial Approval NoticeOct 30, 2025
Report for Q3 2025Oct 31, 2025
Announcement on Voluntary Shareholding Increase Plan by Certain Directors and Senior Management MembersNov 8, 2025
Announcement on Shareholding Increase by Persons Acting in Concert of Actual ControllersNov 13, 2025

All Jiangsu Kanion Pharmaceutical news releases

Follow Jiangsu Kanion Pharmaceutical into a list and get an email when it puts out news.

Follow Jiangsu Kanion Pharmaceutical